Hepatitis C has been a much discussed topic among biotech investors so far this year, mainly due to a new drug, Sovaldi, which treats this potentially fatal diseaseSovaldi is garnering its share of press due to its huge initial sales ($5.8 billion in its first two quarters of rollout). The drug also has been in the news due to its high price tag d...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.